Drugs / gp100 human melanoma peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001439 | Jun 1995 → Apr 2000 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100 human melanoma peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001439 ↗ |
| Modality | Peptide | “nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100” NCT00001439 ↗ |
| Route | Subcutaneous | “gp100 peptide vaccines administered subcutaneously” NCT00001439 ↗ |